Between 2000 and 2007, mortality due to dementia more than doubled; the FDA has granted the rapid designation for an opioid antidote from Purdue Pharma, the pharmaceutical company accused of aggressive marketing OxyContin; the doctors say that the prior authorization interferes with the continuity of care.
More than doubled dementia mortality
Mortality rates due to dementia have more than doubled since 2000, going from 30.5 deaths per 100,000 in 2000 to 66.7 in 2017, according to a national CDC statistics report. These mortality rates varied by age, sex, race and geographical location, and in 2017 most deaths occurred in nursing homes or other long-term care facilities. According to the report, taking into account the mortality of all 4 causes of dementia would have made dementia the third leading cause of death in the United States in 2017.
FDA Fast Tracks Purdue's opioid antidote
The FDA has granted the rapid designation for an experimental opioid overdose drug from Purdue Pharma, the pharmaceutical company currently under investigation and which is facing lawsuits for allegedly aggressive and deceptive commercialization of OxyContin, CNN reported. According to the drug manufacturer, their opioid antidote, the nalmefene hydrochloride injection, has a longer effect than naloxone.
Preliminary authorizations that interfere with care
A report by the American Medical Association found that the use of prior authorization has significantly increased in the last 5 years and the vast majority (85%) of doctors say the process interferes with the continuity of the 39; support. The survey of 1,000 doctors in December 2018 also found that nearly 7 out of 10 doctors have difficulty determining whether the prescription or medical service requires a prior authorization.